Precision Medicine Market Research Report - Global Forecast till 2027

エコシステムプレーヤー(医薬品およびバイオテクノロジー企業、診断会社、ヘルスケアITスペシャリスト/ビッグデータ企業、臨床研究所)、サブマーケット(コンパニオン診断、バイオマーカーベースのテスト、標的治療薬、薬理ゲノミクス(PGX)、分子診断など)、治療薬(がん/腫瘍学、心血管疾患(CVD)、中枢神経系、感染症など)および地域(南北アメリカ、ヨーロッパ、アジア太平洋、中東およびアフリカ)-2027年までの世界予測

ID: MRFR/Pharma/0420-CR | February 2021 | Region: Global | 313 Pages         

1 Report Scope

1.1 Scope of the Study 26

1.2 Precision Medicine: Report Coverage 27

1.3 Research Methodology 29

1.3.1 Research Methodology for the Global Market Study 30

1.3.1.1 Geographical Analysis 30

1.3.1.2 Demand Side & Supply Side Analysis 31

1.3.1.3 Data Synthesis and Bridging 31

1.3.2 Global Precision Medicine: Research Methodology 32

1.3.3 Key Data Point Sources 33

1.3.3.1 Data Points Taken from Secondary Sources 33

1.3.3.2 Data Points Taken from Primary Sources 33

1.4 Report Description 34

2 Executive Summary

3 Market Overview

3.1 Introduction 42

3.2 Market Timeline 42

3.3 Key Participants, Strategies & Developments 50

3.3.1 Government Agencies 50

3.3.2 Academic Institutions 50

3.3.3 Device & Service Providers 51

3.4 Key Market Strategies and Developments 51

3.4.1 Introduction 51

3.4.2 Partnerships, Agreements, and collaborations 52

3.4.3 Mergers & Acquisitions 54

3.4.4 Product Development and Launch 56

3.4.5 Business Expansion/Contracts 57

3.4.6 Patents, Approvals, and Certifications 59

3.4.7 Others (Events & Recognitions) 60

4 Market Dynamics

4.1 Introduction 61

4.2 Market Drivers 62

4.2.1 Patients Involvement in Personal Healthcare 62

4.2.2 Technologies Driving the Market (Next-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)..64

4.2.3 Increase in Genetic Diseases 64

4.2.4 potential for More Targeted Therapies 65

4.2.5 Integration of Big Data Healthcare Companies with Pharma & Biotech Companies 65

4.3 Market Challenges 66

4.3.1 Potential Threat to Personal Data 66

4.3.2 High Diagnostic Cost as a Barrier 67

4.3.3 Potential Risk of Hardware or Software Failure 68

4.3.4 Stringent Regulations and Standards 68

4.3.5 Lack of Awareness about the Possible Applications of Precision Medicine 70

4.3.6 Reimbursement Policies and Regulatory Framework 71

4.3.7 Limited Knowledge About the Application of Test and Techniques 71

4.3.8 Lack of Research and Evidences Creating Hindrances in its Application 72

4.4 Market Opportunities 73

4.4.1 Introduction of Precision Medicine Solutions in Developing Economies 73

4.4.2 Downsizing the Cost of Genome Sequencing to Three Digits 74

5 Industry Dynamics

5.1 Value Chain Analysis 76

5.1.1 Device Manufacturer & Drug Producers 77

5.1.2 Healthcare Providers 77

5.1.3 Healthcare ITs or Big Data Companies 77

5.1.4 Regulators 77

5.1.5 Third Party Payers 78

5.1.6 Patients 78

5.2 Porter Five Force Analysis 78

5.2.1 Bargaining Power of Buyer (Patient) 79

5.2.2 Bargaining Power of Supplier 80

5.2.3 Threat from Substitute 82

5.2.4 Threat from a New Entrant 83

5.2.5 Intensity of Competitive Rivalry 84

6 Consortiums, Certification, Regulations, and Standards

6.1 Introduction 85

6.1.1 Regulatory Bodies 86

6.1.1.1 Food and Drug Administration (FDA) 89

6.1.1.2 Medicines and Healthcare products Regulatory Agency (MHRA) 91

6.1.1.3 Therapeutic Goods Administration (TGA)-Australia 91

6.1.1.4 Conformité Européenne (CE) 92

6.1.2 Consortiums 92

6.1.3 Alliances/Associations 94

7 Global Precision Medicine Market by Ecosystem Players

7.1 Introduction 96

7.1.1 Market Statistics 97

7.2 Pharmaceuticals and Biotechnology Companies 99

7.2.1 Key Market Trends, Developments, and Participants 105

7.2.1.1 Market Trends 105

7.2.1.2 Market Developments 105

7.2.1.3 Key Participants 106

7.3 Diagnostic Companies 107

7.3.1 Key Market Trends, Developments, and Participants 111

7.3.1.1 Market Trends 111

7.3.1.2 Market Developments 112

7.3.1.3 Key Participants 112

7.4 Healthcare it Specialists/Big Data Companies 113

7.4.1 Key Market Trends, Developments, and Participants 119

7.4.1.1 Market Trends 119

7.4.1.2 Market Developments 120

7.4.1.3 Key Participants 121

7.5 Clinical Laboratories 121

7.5.1 Key Market Trends, Developments, and Participants 125

7.5.1.1 Regulatory Bodies and Compliances 125

7.5.1.2 Market Trends 126

7.5.1.3 Key Participants 127

8 Global Precision Medicine Market by Sub-Markets

8.1 Introduction 128

8.1.1 Market Statistics 129

8.2 Companion Diagnostics 131

8.3 Biomarker-Based Test 135

8.3.1 Role of Biobanking into Biomarker 137

8.3.2 Key Participants 141

8.4 Targeted Therapeutics 142

8.4.1 Key Participants 144

8.5 Pharmacogenomics (PGX) 144

8.5.1 Key Market Trends, Developments, and Participants 149

8.5.1.1 Market Trends 149

8.5.1.2 Market Developments 150

8.5.1.3 Key Participants 151

8.6 Molecular Diagnostics 151

8.7 Others 157

8.7.1 Next-Generation Sequencing 159

8.7.2 Consumer Genomics 159

8.7.2.1 Key Participants 159

8.7.3 3D Printing 160

8.7.4 Prosthetics Market 160

8.7.5 Human Tissues Market 160

9 Global Precision Medicine Market by Therapeutics

9.1 Introduction 162

9.1.1 Market Statistics 163

9.2 Cancer/Oncology 164

9.2.1 Market Statistics 165

9.2.2 Types of Cancer 167

9.2.3 Drugs & Tests 170

9.2.4 Key Market Trends, Developments, and Participants 172

9.2.4.1 Market Trends 172

9.2.4.2 Market Developments 172

9.2.4.3 Key Participants 174

9.3 Cardiovascular Disease (CVD) 175

9.3.1 Market Statistics 176

9.3.2 Drugs & Tests 179

9.3.3 Market Trends and Market Developments 180

9.3.3.1 Market Trend 180

9.3.3.2 Market Developments 181

9.3.3.3 Key Participants 181

9.4 Central Nervous System 182

9.4.1 Market Statistics 182

9.4.2 Neurological 184

9.4.2.1 Neurological Drugs & Tests 185

9.4.3 Psychiatric Disorders 186

9.4.3.1 Psychiatric Disorder Drugs & Tests 186

9.4.4 Market Tends & Market Developments 188

9.4.4.1 Market Trends 188

9.4.4.2 Key Developments 188

9.4.4.3 Key Participants 188

9.5 Infectious Diseases 189

9.5.1 Market Statistics 189

9.5.2 Infectious Diseases Drugs & Tests 192

9.5.3 Market Developments & Participants 193

9.5.3.1 Key Developments 193

9.5.3.2 Key Participants 194

9.6 Others 194

9.6.1 Market Statistics 195

9.6.2 Market trends, Developments & Participants 200

9.6.2.1 Market Trends 200

9.6.2.2 Key Developments 200

9.6.2.3 Key Participants 201

10 Global Precision Medicine Market, by Geography

10.1 Introduction 202

10.1.1 Market Statistics 203

10.2 The Americas 204

10.2.1 North America 207

10.2.1.1 US. 208

10.2.1.2 Canada 209

10.2.1.3 Others 210

10.2.1.4 Key Market Trends, Developments, and Participants 210

10.2.1.5 Regulations and Compliances 210

10.2.1.6 Market Trends 210

10.2.1.7 Market Developments 211

10.2.1.8 Key Participants 211

10.2.2 South America 212

10.2.2.1 Key Market Trends, Developments, and Participants 212

10.2.2.2 Regulations and Compliances 212

10.2.2.3 Market Trends 212

10.2.2.4 Key Participants 212

10.3 Europe 213

10.3.1 Key Market Trends, Developments and Participants 216

10.3.1.1 Regulations and Compliances 216

10.3.1.2 Market Developments 216

10.3.1.3 Key Participants 218

10.4 Asia-Pacific (APAC) 218

10.4.1 Key Market Trends, Developments, and Participants 222

10.4.1.1 Market Developments 222

10.4.1.2 Key Participants 223

10.5 Rest of the World/Midde East & Africa (MEA) 223

10.5.1 Africa 225

10.5.1.1 Middle East 226

10.5.2 Key Market Developments and Participants 226

10.5.2.1 Market Developments 226

10.5.2.2 Key Participants 226

11 Company Profiles

11.1 Abbott Laboratories 227

11.1.1 Overview 227

11.1.2 Financials 228

11.1.2.1 Overall Financials 228

11.1.2.2 Financials by Segment 228

11.1.2.3 Financials by Region 229

11.1.2.4 Key Developments 229

11.1.3 SWOT Analysis 231

11.2 Almac Group, Ltd. 232

11.2.1 Overview 232

11.2.2 Financials 232

11.2.3 Key Developments 233

11.2.4 SWOT Analysis 234

11.3 Asuragen, Inc. 235

11.3.1 Overview 235

11.3.2 Financials 235

11.3.3 Key Developments 236

11.3.4 SWOT Analysis 237

11.4 BioMérieux SA 238

11.4.1 Overview 238

11.4.2 Financials 239

11.4.2.1 Overall Financials 239

11.4.2.2 Financials by Region 239

11.4.2.3 Financials by Segment 240

11.4.3 Key Developments 240

11.4.4 Swot Analysis 242

11.5 Cepheid Inc. 243

11.5.1 Overview 243

11.5.2 Financials 244

11.5.2.1 Overall Financials 244

11.5.2.2 Net Revenue by Segment 245

11.5.2.3 Net Revenue by Region 245

11.5.3 Key Developments 246

11.5.4 SWOT Analysis 247

11.6 CETICS Healthcare Technologies GmbH 248

11.6.1 Overview 248

11.6.2 Financials 248

11.6.3 Key Developments 249

11.6.4 SWOT Analysis 250

11.7 GE Healthcare 251

11.7.1 Overview 251

11.7.2 Financials 252

11.7.2.1 Overall Financials 252

11.7.2.2 Net Revenue by Segment 253

11.7.2.3 Financial Summary 254

11.7.3 Key Developments 254

11.8 Glaxosmithkline Plc (GSK) 256

11.8.1 Overview 256

11.8.2 Financials 257

11.8.2.1 Overall Financials 257

11.8.2.2 Financials by Segment 257

11.8.2.3 Financials by Region 258

11.8.2.4 Financials by Therapeutics 258

11.9 Intomics A/S 259

11.9.1 Overview 259

11.9.2 Financials 259

11.9.3 Key Developments 259

11.9.4 SWOT Analysis 260

11.10 Johnson & Johnson 261

11.10.1 Overview 261

11.10.2 Financials 262

11.10.2.1 Overall Financials 262

11.10.2.2 Net Revenue by Segment 262

11.10.2.3 Net revenue by Region 263

11.10.3 Key Developments 263

11.11 Laboratory Corporation of America Holdings 264

11.11.1 Overview 264

11.11.2 Financials 265

11.11.2.1 Overall Financials 265

11.11.2.2 Financials by Segment 266

11.11.3 Key Developments 266

11.11.4 SWOT Analysis 268

11.12 Medtronic 269

11.12.1 Overview 269

11.12.2 Financials 270

11.12.2.1 Overall Financials 270

11.12.3 Key Developments 270

11.13 Novartis 272

11.13.1 Overview 272

11.13.2 Financials 273

11.13.2.1 Overall Financials 273

11.13.2.2 Financials by Region 274

11.13.2.3 Financials by Segment 274

11.14 Pfizer Inc. 275

11.14.1 Overview 275

11.14.2 Financials 276

11.14.2.1 Overall Financials 276

11.14.2.2 Net Revenue by Segment 276

11.14.2.3 Net Revenue by Region 277

11.14.3 Key Developments 277

11.14.4 Swot Analysis 279

11.15 Qiagen 280

11.15.1 Overview 280

11.16 Biobase GmbH (Subsidiary) 281

11.16.1 Overview 281

11.16.2 Financials 282

11.16.2.1 Overall Financials 282

11.16.3 Key Developments (Biobase) 283

11.17 Quest Diagnostics Inc 284

11.17.1 Overview 284

11.17.2 Financials 285

11.17.2.1 Overall Financials 285

11.17.2.2 Net Revenue by Segment 286

11.17.3 Key Developments 286

11.17.4 SWOT Analysis 288

11.18 Randox Laboratories Ltd. 289

11.18.1 Overview 289

11.18.2 Financials 289

11.18.3 Key Developments 290

11.18.4 SWOT Analysis 291

11.19 Roche Holding AG-BR 292

11.19.1 Overview 292

11.19.2 Financials 293

11.19.2.1 Overall Financials 293

11.19.2.2 Net Revenue by Segment 293

11.19.3 Key Developments 294

11.19.4 SWOT Analysis 295

11.20 Sanofi Pharma 296

11.20.1 Overview 296

11.20.2 Financials 297

11.20.2.1 Overall Financials 297

11.20.2.2 Net Revenue by Segment 297

11.21 Takeda Pharmaceutical Company Limited 298

11.21.1 Overview 298

11.21.2 Financials 299

11.21.2.1 Overall Financials 299

11.21.3 Key Developments 299

11.21.4 SWOT Analysis 301

11.22 Teva Pharmaceutical Industries Ltd. 302

11.22.1 Overview 302

11.22.2 Financials 303

11.22.2.1 Overall Financials 303

11.22.2.2 Net Revenue by Segment 303

11.22.2.3 Net Revenue by Segment 304

11.22.3 Key Developments 304

11.22.4 SWOT Analysis 307

11.23 AB-Biotics SA 308

11.23.1 Overview 308

11.24 Caris Life Sciences 309

11.24.1 Overview 309

11.25 HealthCore, Inc. 310

11.25.1 Overview 310

11.26 IBM 311

11.26.1 Overview 311

11.27 InnVentis 312

11.27.1 Overview 312

11.28 Intel Corporation 313

11.28.1 Overview 313

11.29 Molecular Health GmbH 314

11.29.1 Overview 314

11.30 Precision for Medicine 315

11.30.1 Overview 315

12 List of Tables

TABLE 1 LEADING COMPANIES IN THE PRECISION MEDICINE MARKET 37

TABLE 2 DOWNSIZING COST OF GENOME SEQUENCING 74

TABLE 3 FACTORS IMPACTING THE BUYERS BARGAINING POWER 80

TABLE 4 FACTORS IMPACTING THE SUPPLIERS BARGAINING POWER 81

TABLE 5 FACTORS IMPACTING THE THREAT FROM SUBSTITUTE 82

TABLE 6 FACTORS IMPACTING THE THREAT FROM NEW ENTRANT 83

TABLE 7 FACTORS IMPACTING THE DEGREE OF COMPETITION 84

TABLE 8 REGULATORY BODIES IN PRECISION MEDICINE MARKET 87

TABLE 9 CONSORTIUMS IN PRECISION MEDICINE MARKET 93

TABLE 10 ALLIANCES/ASSOCIATIONSIN PRECISION MEDICINE MARKET 94

TABLE 11 GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2020–2027 (USD BILLION) 97

TABLE 12 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES,

2020–2027 (USD BILLION) 100

TABLE 13 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION) 101

TABLE 14 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY,

2020–2027 (USD BILLION) 102

TABLE 15 KEY DEVELOPMENTS IN PHARMA & BIOTECH COMPANIES (2020) 105

TABLE 16 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES,

2020–2027 (USD BILLION) 107

TABLE 17 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION) 108

TABLE 18 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY GEOGRAPHY, 2020–2027 (USD BILLION) 109

TABLE 19 KEY DEVELOPMENTS IN DIAGNOSTIC COMPANIES(2020) 112

TABLE 20 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY SUB-MARKET TYPES, 2020–2027 (USD BILLION) 113

TABLE 21 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION) 114

TABLE 22 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY GEOGRAPHY, 2020–2027 (USD BILLION) 115

TABLE 23 KEY DEVELOPMENTS IN HEALTHCARE IT/BIG DATA COMPANIES(2020) 120

TABLE 24 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY SUB-MARKET TYPES, 2020–2027 (USD BILLION) 122

TABLE 25 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION) 123

TABLE 26 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY GEOGRAPHY, 2020–2027 (USD BILLION) 124

TABLE 27 GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2020–2027 (USD BILLION) 129

TABLE 28 COMPANION DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY ECOSYSTEM PLAYERS, 2020–2027 (USD MILLION) 131

TABLE 29 COMPANION DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 132

TABLE 30 LIST OF APPROVED COMPANION DIAGNOSTIC DEVICES 133

TABLE 31 BIOMARKER: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY ECOSYSTEM PLAYERS, 2020–2027 (USD MILLION) 135

TABLE 32 BIOMARKER: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 136

TABLE 33 LIST OF BIOBANKS 138

TABLE 34 EXAMPLES OF BIOBANKING INITIATIVES ACROSS SELECTED OECD COUNTRIES 139

TABLE 35 TARGETED THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY ECOSYSTEM PLAYERS, 2020–2027 (USD MILLION) 142

TABLE 36 TARGETED THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 143

TABLE 37 PHARMACOGENOMICS: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY ECOSYSTEM PLAYERS, 2020–2027 (USD MILLION) 145

TABLE 38 PHARMACOGENOMICS: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 146

TABLE 39 MOLECULAR DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY ECOSYSTEM PLAYERS, 2020–2027 (USD MILLION) 152

TABLE 40 MOLECULAR DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 153

TABLE 41 OTHER SUB-MARKETS: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY ECOSYSTEM PLAYERS, 2020–2027 (USD MILLION) 157

TABLE 42 OTHER SUB-MARKETS: GLOBAL PRECISION MEDICINE MARKET VALUE,

BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 158

TABLE 43 GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2020–2027 (USD BILLION) 163

TABLE 44 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS,

2020–2027 (USD BILLION) 165

TABLE 45 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2020–2027 (USD BILLION) 166

TABLE 46 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2020–2027 (USD BILLION) 167

TABLE 47 PRECISION MEDICINE DRUGS AND RELEVANT GENES: ONCOLOGY 170

TABLE 48 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO ONCOLOGY 171

TABLE 49 PRECISION MEDICINE MARKET KEY DEVELOPMENTS (2020–2020) 172

TABLE 50 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2020–2027 (USD BILLION) 176

TABLE 51 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2020–2027 (USD BILLION) 177

TABLE 52 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2020–2027 (USD MILLION) 178

TABLE 53 PRECISION MEDICINE DRUGS AND RELEVANT GENES: CARDIOVASCULAR 179

TABLE 54 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO CARDIOVASCULAR 180

TABLE 55 KEY DEVELOPMENTS (2020–2020) 181

TABLE 56 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2020–2027 (USD MILLION) 182

TABLE 57 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2020–2027 (USD MILLION) 183

TABLE 58 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2020–2027 (USD MILLION) 184

TABLE 59 PRECISION MEDICINE DRUGS AND RELEVANT GENES: NEUROLOGY 185

TABLE 60 PRECISION MEDICINE DRUGS AND RELEVANTGENES: PSYCHIATRIC DISORDERS 186

TABLE 61 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO PSYCHIATRIC DISORDERS 187

TABLE 62 PSYCHIATRIC DISORDERS: PRECISION MEDICINE MARKET KEY DEVELOPMENTS (2020–2020) 188

TABLE 63 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS,

2020–2027 (USD MILLION) 189

TABLE 64 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES,

2020–2027 (USD MILLION) 190

TABLE 65 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY,

2020–2027 (USD MILLION) 191

TABLE 66 PRECISION MEDICINE DRUGS AND RELEVANT GENES: INFECTIOUS DISEASES 192

TABLE 67 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS,

2020–2027 (USD MILLION) 195

TABLE 68 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES,

2020–2027 (USD MILLION) 196

TABLE 69 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY,

2020–2027 (USD MILLION) 197

TABLE 70 PRECISION MEDICINE DRUGS AND RELEVANT GENES: OTHER DISEASES 198

TABLE 71 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO OTHER DISEASES 199

TABLE 72 GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2020–2027 (USD BILLION) 203

TABLE 73 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS,

2020–2027 (USD BILLION) 204

TABLE 74 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS,

2020–2027 (USD BILLION) 205

TABLE 75 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS,

2020–2027 (USD BILLION) 206

TABLE 76 EUROPE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS,

2020–2027 (USD BILLION) 213

TABLE 77 EUROPE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS,

2020–2027 (USD BILLION) 214

TABLE 78 APAC: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2020–2027 (USD BILLION) 219

TABLE 79 APAC: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS,

2020–2027 (USD MILLION) 220

TABLE 80 ROW: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2020–2027 (USD MILLION) 224

TABLE 81 ROW: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS,

2020–2027 (USD MILLION) 225

13 List of Figures

FIGURE 1 PRECISION MEDICINE MARKET STUDY 27

FIGURE 2 PRECISION MEDICINE MARKET RESEARCH METHODOLOGY 29

FIGURE 3 DIFFERENT PHASES OF RESEARCH METHODOLOGY FOR THE GLOBAL PRECISION MEDICINE MARKET 30

FIGURE 4 PRECISION MEDICINE MARKET: RESEARCH METHODOLOGY 32

FIGURE 5 GLOBAL PRECISION MEDICINE MARKET SHARE, BY ECOSYSTEM, 2020–2027 (USD BILLION) 38

FIGURE 6 GLOBAL PRECISION MEDICINE MARKET SIZE, BY SUB-MARKET TYPE, 2020–2027 (BILLION) 39

FIGURE 7 GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERPEUTIC APPLICATION, 2020–2027 (BILLION) 40

FIGURE 8 GLOBAL PRECISION MEDICINE MARKET SIZE, BY GEOGRAPHY, 2020 – 2027 (USD BILLION) 41

FIGURE 9 TIMELINE OF PRECISION MEDICINE 43

FIGURE 10 PRECISION MEDICINE MARKET: BENEFITS 45

FIGURE 11 EXAMPLES: APPLIED AREAS OF PRECISION MEDICINE 46

FIGURE 12 ELEMENTS OF PRECISION MEDICINE MARKET TECHNOLOGY 47

FIGURE 13 PRECISION MEDICINE MARKET : DIFFERENT TYPE OF DATA USED BY BIG DATA COMPANIES 48

FIGURE 14 PRECISION MEDICINE MARKET : AREAS OF INTEREST 49

FIGURE 15 PRECISION MEDICINE MARKET : PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2020) 53

FIGURE 16 PRECISION MEDICINE MARKET : MERGERS & ACQUISITIONS (2020) 55

FIGURE 17 PRECISION MEDICINE MARKET : KEY PRODUCT LAUNCH & DEVELOPMENTS (2020) 57

FIGURE 18 PRECISION MEDICINE MARKET : KEY BUSINESS EXPANSIONS & CONTRACTS (2020) 58

FIGURE 19 PRECISION MEDICINE MARKET : KEY PATENTS/ APPROVALS (2020) 59

FIGURE 20 PRECISION MEDICINE MARKET: EVENTS & RECOGNITION (2020) 60

FIGURE 21 PRECISION MEDICINE MARKET DRIVERS AND CHALLENGES 61

FIGURE 22 BENEFITS OF PRECISION MEDICINE TO PATIENTS 63

FIGURE 23 MAJOR BARRIERS CAUSED BY REGULATION AND STANDARDS 69

FIGURE 24 FLOW CHART OF PRECISION MEDICINE MARKET 76

FIGURE 25 PRECISION MEDICINE MARKET : PORTER FIVE FORCE ANALYSIS 79

FIGURE 26 ROLES AND RESPONSIBILITIES OF HEALTHCARE POLICY MAKERS 86

FIGURE 27 ROLE OF FDA IN PRECISION MEDICINE 90

FIGURE 28 CLASSIFICATION OF MEDICAL DEVICES 91

FIGURE 29 GLOBAL PRECISION MEDICINE MARKET BY ECOSYSTEM PLAYERS 98

FIGURE 30 ROLE OF PHARMACEUTICALS AND BIOTECH COMPANIES 103

FIGURE 31 PRECISION MEDICINE MARKET CHALLENGES FACED BY PHARMA & BIOTECH COMPANIES 104

FIGURE 32 DIAGNOSTIC TESTS BENEFITS FOR STAKEHOLDERS 110

FIGURE 33 CHALLENGES FACED BY DIAGNOSTIC COMPANIES 111

FIGURE 34 BENEFITS OF BIG DATA 116

FIGURE 35 TRANSFORMATION OF MEDICINE 117

FIGURE 36 BASIC INGREDIENTS PROVIDED BY BIG DATA FOR PRECISION MEDICINE 118

FIGURE 37 PRECISION MEDICINE MARKET CHALLENGES FACED BY BIG DATA COMPANIES 119

精密医療市場

精密医薬品の評価額は、CAGRで約12614億米ドルに達すると予想されています。または、予測期間(2020-2027)の間、市場の複合年間成長率は12.50%になると予測されています。

セグメンテーション

By Ecosystem Players Pharmaceuticals And Biotechnology Companies Diagnostic Companies Healthcare It Specialists/Big Data Companies Clinical Laboratories
By Sub Markets Companion Diagnostics Biomarker Based Test Targeted Therapeutics Pharmacogenomics (Pgx) Molecular Diagnostics
By Therapeutics Cancer/Oncology Cardiovascular Disease (Cvd) Central Nervous System Infectious Diseases

キープレーヤー

  • Abbott Laboratories (USA)
  • Ab-Biotics Sa (USA)
  • Almac Group Ltd. (UK)
  • Asuragen Inc (USA)
  • Biobase Gmbh (Germany)
  • Biomérieux Sa(France)
  • Caris Life Sciences (USA)
  • Cepheid Inc. (USA)
  • Cetics Healthcare Technologies Gmbh (Germany)
  • Ge Healthcare (USA)

運転手

  • Rising rate of diseases required personalized medicines Health crisis is increasing the demand for individualized medicines
Speak to Analyst Request a Free Sample

精密医療市場の概要

精密医療市場は、最近最も急速に発展している市場の1つです。プレシジョンメディスン評価の推定市場は、2025年までに約1,261億4000万米ドルに達すると予想されています。市場のCAGRまたは複合年間成長率は、予測期間(2017年から2025年)に12.50パーセントになると予測されています。


精密医療業界は、長年にわたって急速に進歩しているヘルスケア分野の今後のトレンドです。個別化医療としても知られる精密医療のトレンドの市場は、2003年に誕生し、それ以来、ヘルスケア業界の市場を支配してきました。これらの個別化医薬品は、ヒトゲノム全体のシークエンシングに取り組む医療部門の主な焦点です。近代的で高度な技術開発は、新しい医学、科学、およびビジネスモデルを提示する多くの機会の道を生み出しました。


精密医療市場は、患者のパーソナルヘルスケアへの関与を可能にし、より的を絞った治療法を個人に提供し、今後数年間の市場の成長を後押しします。超ハイスループット技術や次世代シークエンシング技術などの技術の急速な発展は、精密医療の未来を左右します。さまざまな遺伝病の有病率の増加により、個別化医療市場の可能性は極限に達すると予測されています。ビッグデータヘルスケア企業によるバイオテクノロジーおよび製薬業界の導入は、精密医療の市場成長を推進することになります。


がんの新しい高度な治療は、精密医薬品と密接に関連しています。個人の遺伝子変異は異なり、それを理解することで、臨床医は腫瘍の種類に応じて患者に正確で特定の薬を処方することができます。これらの医薬品は、遺伝子変異に基づく腫瘍との闘いに役立ち、個別化医療業界に大きな需要を生み出しています。乳がんの治療では、医師は現在、患者のための特定の治療法を決定することを可能にするゲノム解析を検討しています。医師は、卵巣がんまたは乳がんの家族歴とともに、女性のBRCA遺伝子変異に関するDNA検査報告を監視しています。


精密医療市場の継続的な発展は、その勢いを達成するために市場の成長を促進するでしょう。バイオテクノロジーおよび製薬業界とビッグデータヘルスケア企業の統合は、近い将来、精密医療業界の市場価値をより高いレベルに予測するもう1つの要因です。


レポートは、予測される市場評価と可能な成長率とともに、精密医療市場の内部情報について説明しています。個別化医療市場に対するCOVID19の影響の分析をカバーし、市場成長の機会と脅威を含む市場のダイナミクスについて説明します。レポートには、市場の主要な著名なプレーヤーが含まれ、市場細分化に関する詳細が記載されています。また、予測される年の精密医療業界の成長に影響を与える可能性のあるいくつかの地域に光を当てます。


COVID19 分析


COVID19のパンデミックの発生は世界中で大混乱を引き起こし、金融部門と医療部門に悪影響を及ぼしました。世界経済の成長率は、より低い程度に向かって低下し始め、回復にはさらに何年もかかるだろう。さまざまな企業や業界が大きな経済的損失に直面し、市場の成長率のより低い段階を目撃しました。ロックダウンの制限により、多くの産業オペレーションと製造プロセスが閉鎖されました。しかし、精密医療情報市場分析によると、この困難な時期でも市場は成長率を維持していました。


世界的な健康危機は、ヘルスケア部門における医薬品に対する莫大な需要をもたらしました。病気の発生率の上昇により、個人の治癒を改善するのに役立つ個別化医薬品が必要になりました。健康危機は深刻化している個別化医薬品の需要を緩和し、精密医療市場の可能性を高めます。ゲノム突然変異病のエスカレートするケースは、精密医療業界の助けを必要とし、予測期間中のブロックチェーンの精密医療サイズの拡大につながるでしょう


マーケットダイナミクス



  • 市場の主な推進力


精密医療市場は世界経済で急速に台頭しており、今後数年間で最大の高みに達するでしょう。超ハイスループットシークエンシングや次世代シーケンシングなどのテクノロジーの最近の開発により、患者の健康に関する理解が深まりました。精密医療の市場は、患者に正確な処方を提供し、精密医療市場の可能性をより大きく前進させるパーソナルヘルスケアに個人を巻き込みます。近年、遺伝病の症例数が大幅に増加しています。遺伝子変異の変化は個人によって異なるため、綿密な検査と個別化医療が必要です。


ノーム医療はがんの治療に非常に役立ちます。そのため、多くのがん治療クリニックがノームを疾患の治療に利用しています。高度なテクノロジーは、医師がさまざまな腫瘍タイプに関する患者の遺伝子変異を理解し、腫瘍のタイプに応じて個人に正確で特定の薬を処方できるようにするのに役立ちます。特定の形態の乳がんでは、患者に対する特定の治療法を決定するために遺伝子変異の分析が必要です。医師は、卵巣がんまたは乳がんの家族歴とともにDNA検査を通じて女性のBRCA遺伝子変異を探し、そのための個別化薬を投与します。これらの治療はすべて、個別化医療業界をより高いレベルに押し上げています。バイオテクノロジーおよび製薬業界とビッグデータヘルスケア企業の統合は、精密医療の成長を幅広くサポートします。



  • 市場にとって大きなチャンス


精密医療市場は長年にわたって急速に活気に満ちており、市場機会の大きさは今後の市場の成長を促進するでしょう。近代的で高度な技術開発により、精密医療業界への需要が高まっています。超ハイスループットシークエンシングや次世代シークエンシングなどの技術開発により、患者に対するより特異的で標的を絞った治療が可能になりました。遺伝病の蔓延の増加は、市場での個別化医療の需要の極端な急増も生み出しています。精密医療診断の洞察を通じて、医師は患者の遺伝子変異を理解し、医師が患者の病気を治すための特定の薬を処方するのを助けることができます。ビッグデータヘルスケア産業による製薬およびバイオテクノロジー産業の導入は、予測期間における精密医療の成長を推進するでしょう。



  • 市場制約


精密医療市場は確実に高みに進んでいますが、診断コストの増加は市場の可能性を妨げる可能性があります。診断と治療のプロセスには大量の個人データが含まれており、それに関連する潜在的な脅威があり、市場の成長を制約する可能性があります。厳格な規制と基準は、個別化医療の市場規模の拡大を妨げています。しかし、遺伝病の蔓延と効果的な解決策の需要は、市場の成長率を維持するでしょう。



  • 市場成長の課題


人々の間での遺伝病と個別化医療の適用についての認識の欠如は、市場の成長を制限しています。規制の枠組みと償還方針は、市場の可能性を妨げる可能性があります。しかし、ヘルスケア分野における個別化医療の需要の高まりは拡大するでしょう



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2027: USD 126.14 Billion
  • 2027: Significant Value
  •   CAGR   12.50 % (2017-2027)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Billion)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Ecosystem Players, Sub-Markets and Therapeutics
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Abbott Laboratories (USA), Ab-Biotics Sa (USA), Almac Group Ltd. (UK), Asuragen Inc (USA), Biobase Gmbh (Germany), Biomérieux Sa (France), Caris Life Sciences (USA), Cepheid Inc. (USA), Cetics Healthcare Technologies Gmbh (Germany), Ge Healthcare (USA), Glaxosmithkline PLC (UK), Healthcore Inc. (USA), IBM (USA), Innventis (Israel), Intel Corporation (USA), Johnson & Johnson (USA), Laboratory Corporation Of America Holdings (USA), Medtronic (USA), Molecular Health Gmbh (Germany), Novartis (Switzerland), Pfizer Inc. (USA), Qiagen (Germany), Quest Diagnostics Inc (USA), Randox Laboratories Ltd. (UK), Sanofi Pharma (France), Takeda Pharmaceutical Company Limited (Japan), and Teva Pharmaceutical Industries Ltd. (Israel)
      Key Market Opportunities   global health crisis resulted in immense demand for medicines in the healthcare sector
      Key Market Drivers

  • rising rate of diseases required personalized medicines
  • health crisis is increasing the demand for individualized medicines


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Precision Medicine Market is projected to grow at an 12.48% CAGR between 2020-2027.

    Precision Medicine Market is predicted to touch USD 126.14 billion by 2027.

    Americas are predicted to have the highest share in the Precision Medicine Market.

    Increasing prevalence of genetic diseases and integration of big data with biotech and pharma companies are driving market growth.

    Strict regulations and standards, threat to personal data, and high diagnostic cost may limit market growth.